Skip to main content
Terug
PCRX logo

Pacira BioSciences, Inc.

Datakwaliteit: 100%
PCRX
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
€ 23,20
▲ € 0,55 (2,43%)
Marktkapitalisatie: 998,09M
Dagbereik
€ 22,30 € 23,21
52-Weeksbereik
€ 18,80 € 27,64
Volume
751.463
50D / 200D Gem.
€ 21,87 / € 23,66
Vorige Slotkoers
€ 22,65

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 141,9 0,3
P/B 1,4 2,9
ROE % 1,0 3,7
Net Margin % 1,0 3,8
Rev Growth 5Y % 7,6 10,0
D/E 0,7 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,95
€ 4,87 – € 5,06
940 M 2
FY2029 € 4,60
€ 4,52 – € 4,70
920 M 2
FY2028 € 5,18
€ 5,10 – € 5,29
960 M 3

Belangrijkste Punten

Revenue grew 7,62% annually over 5 years — modest growth
ROE of 0,96% is below average
Generating 136,66M in free cash flow
P/E of 141,90 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3,99%
Cash machine — converts 1942,86% of earnings into free cash flow

Groei

Revenue Growth (5Y)
7,62%
Revenue (1Y)3,63%
Earnings (1Y)N/A
FCF Growth (3Y)-1,02%

Kwaliteit

Return on Equity
0,96%
ROIC1,84%
Net Margin0,97%
Op. Margin3,87%

Veiligheid

Debt / Equity
0,66
Current Ratio4,54
Interest Coverage1,61

Waardering

P/E Ratio
141,90
P/B Ratio1,44
EV/EBITDA46,04
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,63% Revenue Growth (3Y) 3,74%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -59,05%
Revenue Growth (5Y) 7,62% Earnings Growth (5Y) -36,02%
Profitability
Revenue (TTM) 726,41M Net Income (TTM) 7,03M
ROE 0,96% ROA 0,56%
Gross Margin 71,50% Operating Margin 3,87%
Net Margin 0,97% Free Cash Flow (TTM) 136,66M
ROIC 1,84% FCF Growth (3Y) -1,02%
Safety
Debt / Equity 0,66 Current Ratio 4,54
Interest Coverage 1,61 Dividend Yield 0,00%
Valuation
P/E Ratio 141,90 P/B Ratio 1,44
P/S Ratio 1,37 PEG Ratio -1,53
EV/EBITDA 46,04 Dividend Yield 0,00%
Market Cap 998,09M Enterprise Value 1,29B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 726,41M 700,97M 674,98M 666,82M 541,53M
Net Income 7,03M -99,56M 41,96M 15,91M 41,98M
EPS (Diluted) 0,16 -2,15 0,89 0,34 0,92
Gross Profit 519,37M 530,54M 490,31M 467,53M 401,28M
Operating Income 28,10M -73,37M 87,68M 60,02M 89,92M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,26B 1,55B 1,57B 1,68B 2,08B
Total Liabilities 571,81M 775,17M 704,26M 906,19M 1,34B
Shareholders' Equity 693,11M 778,35M 870,13M 775,01M 730,41M
Total Debt 454,38M 638,85M 586,04M 763,39M 1,13B
Cash & Equivalents 158,55M 276,77M 153,30M 104,14M 585,58M
Current Assets 547,97M 745,13M 509,99M 498,33M 866,05M
Current Liabilities 120,59M 309,92M 97,38M 147,77M 521,12M